Company intelligence / Profile preview

Strike Pharma

Ownership: Private
Development stage: Preclinical

Overview

Strike Pharma’s lead programs are in preclinical development. The company has presented data on its ADAC platform and bi-specific antibody candidates at major scientific conferences, demonstrating progress in precision cancer immunotherapy. No clinical results have been reported as of May 2025[2].

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugates (ADCs)Bi-specific antibodiesImmunotherapeutics
Industry: Biotech

Drug pipeline

4 assets

STRIKE2001-KRAS

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

FyoniBio (cell line development for bi-specific antibody and clinical lead candidate)SciLifeLab Drug Discovery and Development Platform, Uppsala UniversityBIO-X Accelerate Program funding via Swedish Agency for Economic and Regional Growth

Beyond the preview

Go deeper on Strike Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Strike Pharma.

Explore the full profile